Paclitaxel-related nail toxicity

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

William P. McGuire, William J. Hoskins, Mark F. Brady et al. · New England Journal of Medicine · 1996 · 2.9K citations · Full text

Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

M. Piccart · JNCI Journal of the National Cancer Institute · 2000 · 1K citations · Full text

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

Noriyuki Katsumata, Makoto Yasuda, Seiji Isonishi et al. · The Lancet Oncology · 2013 · 468 citations

Gastrointestinal Oncology, Conventional Paclitaxel, Medicine +9

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

John K. Chan, Mark F. Brady, Richard T. Penson et al. · New England Journal of Medicine · 2016 · 355 citations · Full text

Taxane-induced nail changes: incidence, clinical presentationand outcome

Alessandro Marco Minisini, Antonellá Tosti, Alberto Sobrero et al. · Annals of Oncology · 2003 · 169 citations

Pathology, Clinical Dermatology, Dermatology +3